Published in Cancer Cell on December 09, 2013
Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15
Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer (2014) 2.00
Macrophages and therapeutic resistance in cancer. Cancer Cell (2015) 1.95
Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) (2014) 1.74
HIF transcription factors, inflammation, and immunity. Immunity (2014) 1.55
The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 1.44
Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol (2015) 1.24
Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol (2015) 1.15
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis. Nat Rev Drug Discov (2015) 1.14
Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Front Immunol (2014) 1.07
Epithelial-mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov (2016) 0.98
Human breast cancer cells educate macrophages toward the M2 activation status. Breast Cancer Res (2015) 0.97
TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism? Front Immunol (2014) 0.94
Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity. Cancer Cell (2013) 0.93
Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. J Clin Invest (2014) 0.92
Mechanisms driving macrophage diversity and specialization in distinct tumor microenvironments and parallelisms with other tissues. Front Immunol (2014) 0.92
The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol (2016) 0.89
Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm (2016) 0.89
Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer. Onco Targets Ther (2016) 0.86
The emerging role of class-3 semaphorins and their neuropilin receptors in oncology. Onco Targets Ther (2014) 0.86
Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol (2017) 0.86
Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. Front Cell Dev Biol (2016) 0.84
Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol (2015) 0.84
Synthesis and evaluation of multivalent M2pep peptides for targeting alternatively activated M2 macrophages. J Control Release (2016) 0.84
Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia. ACS Nano (2015) 0.84
Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. Oncoimmunology (2015) 0.83
Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene (2015) 0.80
CRC-113 gene expression signature for predicting prognosis in patients with colorectal cancer. Oncotarget (2015) 0.80
Ablation of Neuropilin 1 from glioma-associated microglia and macrophages slows tumor progression. Oncotarget (2016) 0.79
HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity. Nat Commun (2016) 0.79
Circulating soluble neuropilin-1 in patients with early cervical cancer and cervical intraepithelial neoplasia can be used as a valuable diagnostic biomarker. Dis Markers (2015) 0.78
Hypoxia-inducible factors: a central link between inflammation and cancer. J Clin Invest (2016) 0.78
Epidermal growth factor treatment of the adult brain subventricular zone leads to focal microglia/macrophage accumulation and angiogenesis. Stem Cell Reports (2014) 0.78
Genome-wide analysis reveals NRP1 as a direct HIF1α-E2F7 target in the regulation of motorneuron guidance in vivo. Nucleic Acids Res (2015) 0.78
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene (2016) 0.78
Glioblastoma: Defining Tumor Niches. Trends Cancer (2015) 0.78
The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. Nat Commun (2016) 0.78
Macrophages and pancreatic ductal adenocarcinoma. Cancer Lett (2015) 0.77
The impact of hypoxia on tumor-associated macrophages. J Clin Invest (2016) 0.77
Ontogeny of Tumor-associated Macrophages and Its Implication in Cancer Regulation. Trends Cancer (2016) 0.77
Macrophages: Regulators of the Inflammatory Microenvironment during Mammary Gland Development and Breast Cancer. Mediators Inflamm (2016) 0.77
Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer (2017) 0.76
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy. J Clin Invest (2017) 0.76
Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages. Vaccines (Basel) (2015) 0.76
Sixty shades of oxygen-an attractive opportunity for cancer immunotherapy. Ann Transl Med (2015) 0.76
Altering the intratumoral localization of macrophages to inhibit cancer progression. Oncoimmunology (2014) 0.76
Interaction of endothelial cells with macrophages-linking molecular and metabolic signaling. Pflugers Arch (2017) 0.76
Hypoxia-inducible factors: key regulators of myeloid cells during inflammation. J Clin Invest (2016) 0.75
Motor neurons control blood vessel patterning in the developing spinal cord. Nat Commun (2017) 0.75
Macrophage and nerve interaction in endometriosis. J Neuroinflammation (2017) 0.75
Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and Obesity. Front Immunol (2017) 0.75
Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters. Mediators Inflamm (2017) 0.75
Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Mol Med Rep (2016) 0.75
Macrophages as Key Drivers of Cancer Progression and Metastasis. Mediators Inflamm (2017) 0.75
A novel role for myeloid cell-specific neuropilin 1 in mitigating sepsis. FASEB J (2017) 0.75
Sema3A promotes the resolution of cardiac inflammation after myocardial infarction. Basic Res Cardiol (2017) 0.75
New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy. J Immunol Res (2016) 0.75
Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection. Oncotarget (2016) 0.75
The role of the semaphorins in cancer. Cell Adh Migr (2016) 0.75
Macrophage-mediated response to hypoxia in disease. Hypoxia (Auckl) (2014) 0.75
Functional significance of macrophages in pancreatic cancer biology. Tumour Biol (2015) 0.75
Class 3 semaphorins in cardiovascular development. Cell Adh Migr (2016) 0.75
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. EMBO Mol Med (2016) 0.75
S1P Provokes Tumor Lymphangiogenesis via Macrophage-Derived Mediators Such as IL-1β or Lipocalin-2. Mediators Inflamm (2017) 0.75
Ablation of Neuropilin 1 in Myeloid Cells Exacerbates High-Fat Diet-Induced Insulin Resistance Through Nlrp3 Inflammasome in vivo. Diabetes (2017) 0.75
Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. Oncogene (2017) 0.75
Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother (2017) 0.75